Printer Friendly

ALPHA 1 BIOMEDICALS, INC., ANNOUNCES LAWSUIT BY SCICLONE PHARMACEUTICALS, INC.

 BETHESDA, Md., Sept. 24 /PRNewswire/ -- Alpha 1 Biomedicals, Inc. (NASDAQ: ALBM), announced today that SciClone Pharmaceuticals, Inc. (NASDAQ-NMS: SCLN), has filed a motion in the U.S. District Court for the Northern District of California seeking certain preliminary injunctive relief pending the outcome of an arbitration proceeding between Alpha 1 and SciClone.
 SciClone, under a license agreement entered into in 1990, holds a license from Alpha 1 to commercialize Thymosin alpha 1 in all countries of the world other than the United States, Canada, Europe, Israel and Korea. On July 26, 1993, Alpha 1, as previously announced, initiated an arbitration proceeding under the license agreement to resolve a number of outstanding contractual disputes. In its response on Aug. 30, 1993, SciClone introduced several counterclaims against Alpha 1, including allegations that Alpha 1 (1) has failed to file, prosecute, extend or maintain certain patents and patent applications in SciClone's territory, (2) has not proceeded diligently with preparations to supply SciClone with bulk Thymosin alpha 1 for commercial sale and (3) has not provided SciClone with certain technical data and information and with technical assistance and support.
 In its motion for preliminary injunctive relief, which is based chiefly on the same allegations made in the arbitration proceeding, SciClone requests (1) the issuance of an order declaring that a contingent manufacturing license which would allow SciClone to manufacture Thymosin alpha 1 for sale in its territory has become operative and (2) transferring to SciClone all powers necessary to file, prosecute, maintain and extend patents and patent applications in its territory. A hearing on SciClone's motion has been scheduled for Oct. 7, 1993.
 According to Vincent F. Simmon, Alpha 1's president and chief executive officer, "We believe that the claims made by SciClone are completely lacking in merit and they are being vigorously contested."
 Alpha 1 Biomedicals, Inc., is engaged in the development of pharmaceutical products for the treatment of chronic viral diseases, immune disorders and cancer. The company's lead drug, Thymosin alpha 1, is currently in U.S. clinical trials for the treatment of chronic hepatitis B, chronic hepatitis C and AIDS.
 -0- 9/24/93
 /CONTACT: Vincent F. Simmon, Ph.D., president and CEO, Alpha 1 Biomedicals, 301-564-4400, or Anita Monteith-Dixon of Long Ridge Associates, 203-790-0647, for Alpha 1 Biomedicals/
 (ALBM SCLN)


CO: Alpha 1 Biomedicals, Inc.; SciClone Pharmaceuticals, Inc. ST: Maryland IN: MTC SU:

DC-MH -- DC018 -- 5446 09/24/93 13:24 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 24, 1993
Words:402
Previous Article:ACTON CORPORATION ANNOUNCES CONTRACT FOR SALE OF MARYLAND CABLE SYSTEM
Next Article:HEALTH CARE FINANCING ADMINISTRATION SELECTS DIRECTOR OF MEDICAID BUREAU
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters